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Alzheimer’s disease (AD) is a progressive and irreversible neurological disorder that
impairs the living quality of old population and even life spans. New compounds have
shown potential inneuroprotective effects in AD, such as GFKP-19, a 2-pyrrolidone
derivative which has been proved to enhance the memory of dysmnesia mouse. The
molecular mechanisms remain to be established for these drug candidates. Large-scale
phosphoproteomic approach has been evolved rapidly in the last several years, which
holds the potential to provide a useful toolkit to understand cellular signaling underlying
drug effects. To establish and test such a method, we accurately analyzed the deep
quantitative phosphoproteome of the neuro-2a cells treated with and without GFKP-
19 using triple SILAC labeling. A total of 14,761 Class I phosphosites were quantified
between controls, damaged, and protected conditions using the high resolution mass
spectrometry, with a decent inter-mass spectrometer reproducibility for even subtle
regulatory events. Our data suggests that GFKP-19 can reverse Aβ25−35 induced
phosphorylation change in neuro-2a cells, and might protect the neuron system in two
ways: firstly, it may decrease oxidative damage and inflammation induced by NO via
down regulating the phosphorylation of nitric oxide synthase NOS1 at S847; Secondly, it
may decrease tau protein phosphorylation through down-regulating the phosphorylation
level of MAPK14 at T180. All mass spectrometry data are available via ProteomeXchange
with identifier PXD005312.
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive and irreversible neurological disorder characterized by
memory and cognitive impairment. AD is currently involved in 50–70% of dementia cases with
half of people over 85 years of age suffering from it (Anand et al., 2014; Imtiaz et al., 2014). It is
estimated that the prevalence of AD in year of 2050 would reach 88 million cases worldwide (Van
Cauwenberghe and Van Broeckhoven, 2016).
Yu et al. Phosphoproteomics for Drug Mechanisms in Neuronal Cells
Among the medicines approved by the U.S. Food and Drug
Administration (FDA), Donepezil, Galantamine, Reivastigmine,
and Tacrine, for instance, are cholinesterase inhibitors dealing
with the loss of cholinergic neurons (Amemori et al., 2015),
while memantine has the effect to block the cytotoxicity of excess
extracellular glutamate on neurons as an N-Methyl-D-aspartate
receptor (NMDAR) antagonist (Arbor et al., 2016). It seems
that most of the current therapeutic drugs for AD are designed
to provide symptomatic treatment rather than to restore the
declined brain function.
The two main neuropathological characteristics of AD have
been recognized, namely senile plaques (SPs) and neurofibrillary
tangles (NFTs), which are, respectively, associated to amyloid β
(Aβ) peptides and hyperphosphorylated tau protein (Holtzman
et al., 2011; Marsden et al., 2011). With important functional
consequences in neurogenesis, amyloid precursor protein (APP)
could be cleaved by β-secretase at the N-terminal of an Aβ
sequence, and then cleaved by γ-secretase subsequently to
produce an Aβ fragment (De Strooper, 2010). Among these
key molecules, Aβ is a peptide with 40∼42 amino acids
most commonly in length, aggregation of which could lead
to NFTs, vascular damage, neuronal loss, and even dementia
(Hardy and Higgins, 1992). Tau is a microtubule-associated
protein (MAP) necessary for stabilizingmicrotubules, and proper
phosphorylation of tau within the microtubules is required
for neurite outgrowth (Lindwall and Cole, 1984; Caceres
and Kosik, 1990). Nevertheless, hyperphosphorylated tau has
been validated in AD, which is able to further promote its
dissociation from microtubules and thus resulting in protein
destabilization and disruption of neuronal transport (Garcia and
Cleveland, 2001). Moreover, mitochondrial dysfunction has been
found in multiple AD tissues (Swerdlow, 2002). Accordingly
the existing mitochondrial cascade hypothesis assumes that
it is the brain mitochondrial dysfunction in AD that induce
amyloidosis and tau phosphorylation (Swerdlow and Khan,
2004). Furthermore, memory impairment and dementia are
common symptoms of AD. Significant cholinergic dysfunctions
in central nervous system of AD had been found. These
studies, combined with the emerging role of cholinergic system
(Drachman and Leavitt, 1974), led to cholinergic hypothesis
which proposes that cognitive disorder in patients with AD
is dramatically associate to the loss of cholinergic neurons
in the basal forebrain (Bartus et al., 1982). Based on the
above mechanisms, acetylcholinesterase (AChE) inhibitors, such
as donepezil, galantamine, and rivastigmine and NMDAR
antagonist like memantine have been common medicines
Abbreviations:AD, Alzheimer’s disease; SILAC, stable isotope labeling with amino
acids in cell culture; Aβ, amyloid β; NFTs, neurofibrillary tangles; MS, mass
spectrometry; LC-MS/MS, liquid chromatography-tandem mass spectrometry;
FC, fold change; FBS, fetal bovine serum; FASP, filiter-aided sample preparation
method; HPLC, high-performance liquid chromatography; QE, Q Exactive; HF,
Q Exactive HF; GO, Gene Ontology; Ab vs. Con, Aβ25−35/Control; GF vs. Con,
(Aβ25−35+GFKP-19)/Control; GF vs. Ab, (Aβ25−35+GFKP-19)/Aβ25−35; NOS,
nitric oxide synthase; ASPP2, apoptosis-stimulating protein of p53; PP1, protein
phosphatase 1; PP2B, protein phosphatase 2B; FYN, tyrosine-protein kinase;
MARK, microtubule-associated protein/microtubule affinity-regulating kinase;
MAPK, mitogen-activated protein kinase.
for AD. Considering inflammation and oxidative damage are
reported in AD (Galimberti and Scarpini, 2011) and anti-
inflammatory drugs and antioxidants have been made to slow
the progression of AD (Cole and Frautschy, 2010; Lee et al.,
2010).
With its high sensitivity, high accuracy and high selectivity
recently achieved, mass spectrometry (MS) increasingly plays
a vital role in biomarker discovery, pharmaceutical research,
and in revealing molecular mechanisms of drug actions and
activities (Aebersold and Mann, 2003, 2016). In the research
field of AD, for example, Lynn et al. utilized a 2-dimensional
liquid chromatography-tandemmass spectrometry (LC-MS/MS)
and the isotope coded affinity tag (ICAT) method to identify,
quantify and distinguish potentially interacting mitochondrial
proteins in short postmortem temporal pole specimens with
mild cognitive impairment, early AD, late-stage AD and age-
matched normal control subjects (Lynn et al., 2010). Similarly,
an LC-MS/MS based approach was developed by Hejazi et
al to investigate the content of sphingomyelin, ceramide,
and galactosylceramide in hippocampus from AD and control
subjects, which could be further applied for lipid analysis
(Hejazi et al., 2011). Also, Dillen et al. set up a screening
UHPLC–MS/MS method for analysis of amyloid peptides in
cerebrospinal fluid, thus laying foundation for the preclinical
study (Dillen et al., 2011). Currently, despite the development
of label-free proteomic methods, the isotopic labeling methods
still present the most accurate quantification approach, especially
for those regulations with a small fold change (FC) (Walther
et al., 2015). Stable isotope labeling by amino acids in cell
culture (SILAC) (Ong et al., 2002) is a powerful metabolic
labeling strategy in MS-based quantitative proteomics, when
combined with phosphoproteomics can provide efficient and
robust help to test quantitative changes in phosphorylation
sites (Dengjel et al., 2007; Dephoure et al., 2008; Hilger
et al., 2009). The combination of phosphoproteomics and
SILAC labeling is therefore very promising to be tested for
analyzing post-translational regulations in AD related research
areas.
As an example, we selected GFKP-19, which is a 2-pyrrolidone
derivative compound, and could be a promising drug candidate
for AD treatment. The pyrrolidone derivative racetam drugs,
such as aniracetam is an ampakine nootropic with glutamatergic
activity and neuroprotective potential (Koliaki et al., 2012).
The 2-pyrrolidone clausenamideare is an anti-dementia drug
candidate and been reported to inhibit the cytotoxicity of
beta amyloid, tau hyperphosphorylation and neurodegeneration
(Hu et al., 2010; Chu and Zhang, 2014; Chu et al., 2016).
To mimic the injury of neuron cells in AD, we used the
active Aβ25−35 peptide (peptide containing the 25–35 th amino
acids of Aβ). Aβ25−35 peptide exhibits the similar cytotoxic
properties of the full-length protein Aβ1−42, and has been
reported to be the active fragment of Aβ1−42 (Pike et al.,
1995; Clementi et al., 2005). In previous studies, Aβ25−35
treatment can induce apoptosis in many mammalian cell lines
in vitro. To determine if GFKP-19 can remit Aβ25−35 induced
effect and the mechanisms underlying its neuroprotective
effects, we carried out a phosphoproteomic study measuring
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the cellular signaling changes in different states of neuro-
2a cell by DMSO, Aβ25−35 alone or Aβ25−35 together with
GFKP-19 treatment. The phosphorylation of tau increased after
Aβ25−35 treatment, and the increase can be reversed by GFKP-
19. Interestingly, the changes in the phosphorylation of tau
kinases also increased during Aβ25−35 treatment and decreased
with the addition of GFKP-19. The comprehensive profiling of
phosphorylation regulation events by SILAC and MS provides
a general framework for understanding drug actions, which is
for the first time reported for the AD relevant drug candidate
compounds.
MATERIALS AND METHODS
Materials
Aβ25−35 was purchased from Sigma (Sigma, A4559). N2
supplement was purchased from Gibco (Gibco, 17502048). As
an example of 2-pyrrolidone derivative compounds GFKP-19
was kindly provided by a collaboration laboratory, which wishes
to not release the detailed structure of this compound along
with the present paper. Aβ25−35 was dissolved in DMSO at a
concentration of 3 mM. GFKP-19 was dissolved in DMSO at
a concentration of 10 mM. 3-(4, 5-dimethylthiazolyl-2)-2, 5-
diphenyl tetrazolium bromide (MTT) was purchased from MP
Biomedicals (MP Biomedicals, 02102227). The dialyzed fetal
bovine serum (FBS) was from Hyclone (Hyclone, SH30079.03).
The Amicon Ultra 15 mL centrifugal filter with a membrane
NMWL of 30 kDa was purchased from Merck Millipore (Merck
Millipore, UFC903024).
Cell Culture
Neuro-2a cells purchased from American Type Culture
Collection (ATCC, CCL-131) were cultured in DMEM media
supplemented with 10% FBS, 1% penicillin/streptomycin,
growing in humidified incubator at 37◦C and 5% CO2. N2
supplement (Gibco, 17502048) was used as a serum-free
supplement during drug treatment. Neuro-2a cells were evenly
seeded into 96-well plates with a density of 5 × 103 cells per
well. At the second day, cells were pretreated with or without
GFKP-19 (0.1 or 1 µM) for 1 h, and Aβ25−35 (1 µM) was added
in the presence of GFKP-19 and all cells were incubated for
another 24 h. Control cells were treated with corresponding
concentration of DMSO.
Determination of Cell Viability
Cell viability was measured by MTT assays (Mosmann, 1983;
Ulukaya et al., 2004). After treatments above, cells were incubated
with 0.5 mg/mL MTT for 4 h. Then, the supernatant was
removed carefully and 150 µL DMSO was added to dissolve the
formazan. The plate was shaken for 10 min, and absorbance at
490 nm was obtained with a microplate reader (BIO-RADModel
3550).
SILAC Labeling and Sample Preparation
DMEM media for SILAC (Thermo, 89985) was supplemented
with 10% dialyzed FBS, 1% penicillin/streptomycin and before
drug treatment, and the dialyzed FBS was replaced by N2
supplement during drug treatment. The light SILAC amino acids
L-lysine (Sigma, L8662) and L-arginine (Sigma, A8094), the
medium SILAC amino acids L-lysine-2H4 (Sigma, 616192) and
L-arginine-13C6 (Sigma, 643440), or the heavy SILAC amino
acids L-lysine-13C156 N2 (Sigma, 608041) and L-arginine-
13C156 N4
(Sigma, 608033) were added with a final concentration of 28
mg/L for the arginine and 50 mg/L for the lysine amino acids
to generate light, medium, and heavy SILAC-labeling media.
Neuro-2a cells were labeled as previously published with light,
medium and heavy SILAC-labeling media (Ong and Mann,
2006). After eight passages, full incorporation of SILAC amino
acid was confirmed.
Light SILAC-labeling cells were taken as controls, whereas
medium SILAC-labeling cells were treated with Aβ25−35 (1
µM) for 4 or 24 h, and heavy SILAC-labeling cells were
pretreated with GFKP-19 for 1 h followed exposure to Aβ25−35
(1 µM) and GFKP-19 for another 4 or 24 h. All cells
were, respectively, lysed in buffer containing 4% SDS, 0.1M
DTT, 100 mM tris (pH 7.5). The protein concentrations
were evaluated by tryptophan fluorescence emission assay
(Kulak et al., 2014) and evaluated by SDS-polyacrylamide gel
electrophresis (SDS-PAGE). 100 ng/µL tryptophan was used
to build a standard calibration curve (0, 0.125, 0.25, 0.5, 0.75,
100, and 150 µL), and 1 µL of sample was diluted in 200
µL of 8 M urea for reading protein amount. An excitation
wavelength of 295 nm was adopted to determine protein
concentrations whereby tryptophan fluorescence emission at
350 nm. The assaying instrument used was SpectraMax M5
(Molecular Devices, Sunnyvale, CA). Protein extracts derived
from different treatments were then mixed at the ratio of
1:1:1 at the protein level. A total of 15mg protein mixture
was alkylated with iodoacetamide and digested by trypsin
following the filiter-aided sample preparation method (FASP)
reported (Wisniewski et al., 2009). The enzymatic hydrolysis
efficiency was around 40∼50%. The peptides were subjected
to TiO2 enrichment to get phosphopeptides as described
below.
TiO2 Enrichment of Phosphopeptides
Phosphopeptides were enriched by using Titansphere-
chromatography (TiO2) as described (Thingholm et al.,
2006; Selenica et al., 2007) with minor modifications. Briefly,
1mg of slurry of 5 µm Titansphere material (GL Sciences) in
80% ACN/1% TFA containing saturated glutamic acid was added
directly to the 1mg tryptic peptides. The slurry was incubated
for 15–30 min at room temperature with end-over-end rotation,
spunbriefly on a bench-top centrifuge, and the supernatant was
collected. Titansphere material with phosphopeptides bounded
was washed two times with 400 µL 30% ACN/0.5% TFA and
2 times with 400 µL 70% ACN/0.1% TFA, then transferred
on top of a C8 disc (Empore) placed in 200 µL pipette-tip.
Bound phosphopeptides were eluted by passing 1 times 50 µL
0.6% NH4OH/20% ACN and 2 times 50 µL 1% NH4OH/40%
ACN through the beads. Elutes were then dried almost to
completeness. Normally the yield is 1% of the original peptides
input. All phosphopeptides got at this step were subjected to
fractionation.
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Phosphopeptide Fractionation by High-pH
Reversed-Phase LC
Samples were separated by high-pH reversed-phase high-
performance liquid chromatography (HPLC). The fractionation
procedure was modified from previously described protocol
(Batth et al., 2014). AWaters Xbridge BEH C18 2.5µm 3.0× 100
mm XP column and an Agilent 1290 HPLC were used. Mobile
phase A: 10 mM ammonium formate, 100%H2O (adjusted to pH
10 with ammonium hydroxide); B: 10 mM ammonium formate,
10% H2O, 90% ACN (adjusted to pH 10 with ammonium
hydroxide). Dried phosphopeptides were dissolved in mobile
phase A. The temperature of the column was operated at 45◦C.
After loaded onto the column, samples were separated using a 66
min gradient at a flow rate of 200 µL/min, as follows: 0 min 5%
B; 50 min 25% B; 54 min 60% B; 56 min 70% B; 61 min 70% B;
63 min 5% B; 66 min 5% B. All fractions were collected at 2 min
intervals. 28 fractions were collected between 0 and 56 min and
were pooled into 14 fractions by combining fractions (1 and 15
were combined as fraction 1; 2 and 16 were combined as fraction
2; 3 and 17 were combined as fraction 3, and so on, until 14 and
28 as fraction 14).
LC-MS/MS Analysis
All LC-MS/MS analysis were performed on an EASY n-LC
1000 system directly connected to a Q Exactive (Thermo Fisher
Scientific, San Jose, CA) or a Q Exactive HF (Thermo Fisher
Scientific, San Jose, CA) mass spectrometer which equipped with
a nanospray ion source. Phosphopeptide fractions were dissolved
in solvent A (0.1% formic acid, 100% H2O) and loaded onto a
reversed-phase column, which was packed in-house with 3 µm
C18 ReproSil particles (Dr. Maisch GmbH). The inner diameter
of the column was 75 µm. The solvent B was 0.1% formic acid in
acetonitrile. Samples were separated with a 2 h gradient at a flow
rate of 300 nL/min. The gradient was set up as follows: 0–4 min,
3–4% B; 106 min, 20% B; 114 min, 35% B; 117–120 min, 90% B.
Each sample was analyzed twice by Q Exactive or Q Exactive HF,
respectively.
For Q Exactive, the instrument parameters were set as: The
scan range was between 300 and 1500m/z and full scan resolution
was set at 70,000; fragmentation was performed with the high-
energy collisional dissociation (HCD) with a normalized collision
energy (NCE) of 28%; one full scan was followed by 15 data-
dependentMS/MS scans with a resolution of 17,500 and isolation
window of 2.0 m/z.
For Q Exactive HF, the instrument parameters were as follows:
The full scan used a mass window of 350–1800 m/z at a target
resolution of 60,000; precursor ions were fragmented by HCD
with a NCE of 27%; one full scan was followed by 20 data-
dependentMS/MS scans with a resolution of 30,000 and isolation
window of 1.6 m/z.
The MS parameters are firstly set up according to the vender’s
instructions and then optimized in house to maximize the
analytical power of each machine.
Data Analysis
The raw data files were processed using software MaxQuant
(Cox and Mann, 2008) version 1.5.1.0 with an false-discovery
rater (FDR) <0.01 at all the levels of proteins, peptides
and modifications, to generate peak lists. The MS/MS spectra
were searched against the Mouse UniProt FASTA database
(July 2016) containing 51418 entries. Enzyme specificity was
set to trypsin, allowing for cleavage N-terminal to proline
and between aspartic acid and proline. The search included
cysteine carbamidomethylation as a fixed modification and
N-acetylation of protein, oxidation of methionine and/or
phosphorylation of serine, threonine tyrosine residue (STY) as
variable modifications. The missed cleavage number allowed
was set as no more than 3. The SILAC based quantification
of peptides and proteins was also performed by MaxQuant.
SILAC ratios were normalized so that the median ratio was 1
to correct unequal sample mixing. Bioinformatics analyses were
carried out with Microsoft Excel, GraphPad, Perseus (Tyanova
et al., 2016), and R (https://www.r-project.org/) statistical
computing software. Functional annotations were made through
UniProtKB (http://www.uniprot.org/uniprot/), the Database for
Annotation, Visualization and Integrated Discovery (DAVID)
(https://david.ncifcrf.gov/), motif-x (Schwartz and Gygi, 2005),
and Ingenuity Pathway Analysis (IPA, version 8.5, Ingenuity
Systems, Redwood City, CA). Interaction network was made
with software Cytoscape (http://www.cytoscape.org) and the
physical interaction was provided by the SIGnaling Network
Open Resource (SIGNOR) (Perfetto et al., 2016). Categorical
annotation was performed in the Perseus software environment
(Tyanova et al., 2016), which is a following up analysis tool in
MaxQuant workflow. Categorical annotation was supplied in the
form of GO biological process, molecular function, and cellular
component. Enrichment for these categories was evaluated by
Fisher exact test. Multiple hypothesis testing was controlled
by using a Benjamini-Hochberg FDR threshold of 0.02. The
annotation matrix algorithm was used to compute the difference
of any significant protein annotation term from the overall
intensity distribution as described (Cox et al., 2012). Motif-X
was used to test for significantly overrepresented motifs, with
the following parameters: P-value threshold ≤ 1.0E-6, with the
entire mouse database as background database. The fold increase
of motif was visualized with the Pheatmap package in R.
RESULTS AND DISCUSSIONS
GFKP-19 Suppresses the Aβ25−35 Induced
Cytotoxicity in Neuro-2a
To determine whether GFKP-19 can protect neuro-2a cells (a
brain neuroblastoma cell line) against the cytotoxicity induced
by Aβ25−35, neuro-2a cells were treated with 1 µM Aβ25−35 in
the absence or presence of GFKP-19 at different doses. When
treated with GFKP-19 and Aβ25−35, cells were pretreated with
GFKP-19 for 1 h before Aβ25−35 was added in. According to cell
viability assayed by MTT method, the applicable concentration
of Aβ25−35 was decided according to the results of prevent
experiments (Figure S1A) and previous report (Shih et al.,
2011). Furthermore, we found that the treatment with Aβ25−35
significantly decreased cell viability as assessed, and GFKP-19 was
able to reverse the change (Figure 1A and Figure S1B). Thus,
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FIGURE 1 | Schematic overview of experiment. (A) GFKP-19 can reverse the cytotoxic effect of Aβ25−35 in neuro-2a. Determination of the cell viability of
Neuro-2a after treatment with Aβ25−35 in the absence or presence of GFKP-19 was carried out cells by MTT assay. Neuro-2a cells were exposed to different
concentrations of GFKP-19 (0, 0.1, 1 µM) combined with 1 µM Aβ25−35 for 24 h. The cell viability was determined by MTT assay (n = 5, **P < 0.01 vs. control,
##P
< 0.01 vs. Aβ25−35-treated group). (B) Flow diagram of the SILAC-based quantitative phosphoproteomics analysis. Neuro-2a cells cultured in light, medium and
heavy SILAC-labeling media was severally treated with DMSO as control, Aβ25−35 (1 µM) or Aβ25−35 (1 µM) combined with GFKP-19 (1 µM) for 4 or 24 h. Cell
lysates to be compared were mixed, trypsin digested using filter-aided sample preparation (FASP), enriched on TiO2 beads to obtain phosphopeptides, fractionated
with high pH reversed-phase and analyzed by online LC-MS/MS. Q Exactive and Q Exactive HF were used. (C) Overview of the LC-MS/MS results.
the above cell viability measurements qualified the samples for
further proteomic analysis.
Quantitative and Comprehensive
Phosphoproteome Analysis in Neuro-2a
Cells
To gain global insight into the protective mechanism of GFKP-
19, we combined the quantification method SILAC, high-pH
reversed phase HPLC for fractionation, TiO2 chromatography
for phosphopeptide enrichment and high accuracy mass
spectrometry characterization (Figure 1B and Methods). The
study was carried out on neuro-2a cells, which were cultured in
light, medium and heavy SILAC-labeling media paralleling three
different treatment conditions selected based on the cytotoxicity
experiments (DMSO, 1 µM Aβ25−35, 1 µM Aβ25−35 + 1 µM
GFKP-19). After treated with drugs for 4 or 24 h, cells were lysed
and the proteins were mixed at the ratio of 1:1:1 and digested
by trypsin with the method FASP. Subsequently, peptides were
incubated with TiO2 and phosphopeptides were enriched. Next,
phosphopeptides of each sample were separated into 14 fractions
to decrease the complexity of the samples. The light, medium
and heavy stable isotope labeled phosphopeptides were detected
with highly accurate LC-MS/MS which incorporates a nanoLC
system and a Q Exactive (QE) or a Q Exactive HF (HF). QE
is a high-performance quadrupole Orbitrap mass spectrometer
(Michalski et al., 2011) and HF denotes the improved version
of QE which feature several innovations (Scheltema et al.,
2014). Mass spectrometric data generated from QE and HF
of three experiment groups was searched in MaxQuant using
rigorous criteria. Totally, 25715 phosphosites were identified,
corresponding to 5221 phosphoproteins. Among them, 18505
Class I phosphosites (of which localization probability is at least
0.75 and the score difference is 5 or higher, Table S1) (Pan et al.,
2009) were identified and 14761 of them (that is, 80%) were
quantified (Figure 1C).
Next, we analyzed the coverage of cellular functions
of the deep phosphoproteome measured. To do so, we
compared the Gene Ontology (GO) annotation for cellular
compartment between murine genome and identified
phosphoproteins in neuro-2a cells. GO cellular component
analysis, using DAVID, revealed organelle, cytoplasm, nucleus,
cytoskeleton, chromosome, chromatin, endosome and vesicle
to be overrepresented, indicating that the functions of these
parts of cells are based on significant phosphorylation. As
expected, extracellular proteins in membrane, focal adhesion
and extracellular region were underrepresented (Figure 2A).
This is in agreement with previous reports proving low
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FIGURE 2 | The fractionated phosphopeptides were analyzed by an EASY n-LC 1000 system directly connected to a Q Exactive (QE) or a Q Exactive
HF (HF). (A) Distribution of phosphoproteins identified in cells. Identified phosphorylation proteins were assigned to DAVID GO terms for cellular component. Numbers
of proteins belonging to each GO term are demonstrated as percentages of the total number of proteins. GO terms significantly over- and under-represented are
marked [fold enrichment ≥ 1.4 or ≤ 0.67, P ≤ 0.01 (**)]. (B) Function classification of phosphoproteins identified. The sorting was done with Ingenuity IPA and the bar
plot was generated with GraphPad. (C) Scatter plots of the log-transformed ratios Aβ25−35/Control (Ab vs. Con), (Aβ25−35+GFKP-19)/Control (GF vs. Con), and
(Aβ25−35+GFKP-19)/Aβ25−35 (GF vs. Ab) demonstrate the correlation between QE results and HF results. Black dash lines represent 1.5 FC. The correlation
coefficient (R) were calculated using spearman.
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phosphorylation in the extracellular matrix (Weintz et al., 2010).
The phosphoproteins identified were classified with Ingenuity
IPA for protein class analysis (Figure 2B). These results suggest
the phosphoproteome reflected essential biological functions,
such as kinase (N = 344), phosphatase (N = 99), transcription
regulators (N = 649) and other processes and their regulations
between conditions, demonstrating the direct relevance of
studying phosphoproteome in Aβ cytotoxicity.
Analysis of Global Extent of
Phosphoproteomic Regulation
We then focused on the quantified phosphoproteomic regulation.
Benefiting from the fact that the experimental replicates were
performed at two independent mass spectrometers and analyzed
separately, we first correlated the ratios Aβ25−35/Control (Ab
vs. Con), (Aβ25−35+GFKP-19)/Control (GF vs. Con) and
(Aβ25−35+GFKP-19)/Aβ25−35 (GF vs. Ab) obtained from two
mass spectrometer (QE and HF). We concluded three important
points in our biological and experimental system. Firstly,
the global regulation of phosphoproteome is minor between
conditions, because the fold-changes (FCs) of majority (>90%)
of the phosphosites remained below 1.5 FCs. Also, GF vs. Con at
4 h only have minor change suggesting that GFKP-19 has small
effect on normal neuro-2a cells. This validates our experimental
approach where specific, rather than broad, phosphoprotein
regulations (e.g., those triggered by cell death) were captured.
Secondly, we found the correlations of Aβ25−35/Control (Ab vs.
Con) and (Aβ25−35+GFKP-19)/Control (GF vs. Con), as well as
the numbers of significantly regulated phosphorylation events
were both higher at 4 h compared to those of 24 h (Figure 2C).
For the 4 h data of QE and HF, 5.5 and 6.3% of the phosphosites
have the FC of Ab vs. Con at least 1.5; 1.3 and 2.0% of the
phosphosites have the FC of GF vs. Con at least 1.5; 4.0 and
4.7% of the phosphosites have the FC of GF vs. Ab at least
1.5. For the 24 h data of QE and HF, 2.1 and 2.7% of the
phosphosites have the FC of Ab vs. Con at least 1.5; 1.2 and
1.3% of the phosphosites have the FC of GF vs. Con at least
1.5; 1.0 and 1.5% of the phosphosites have the FC of GF vs.
Ab at least 1.5. This means that 4 h is a good time point to
inspect phosphorylation regulation, while the status at 24 h
only have minor phosphoproteomic changes. This is consistent
to the rapid responsive role of phosphorylation in cellular
systems (Roux and Thibault, 2013). Last but not the least, we
managed to obtain overall decent correlations between the data
sets generated from the two mass spectrometers, despite of the
global phosphoproteomic changes were minor. The correlation
of the repeat experiments between QE and HF can be seen in
Figure S2A. As expected, HF, which has the higher instrumental
configuration, generated a larger data set compared to QE (Figure
S2B). The biological compositions of phosphoproteome reflected
by the two instruments are also very consistent. Just as an
example, for the 4 h data of QE, identified phosphosites of class
I sites consist of 88.3% phosphor-Ser sites, 11.2% phosphor-Thr
sites, and 0.5% phosphor-Tyr sites; for the 4 h data of HF, most
phosphosites of class I sites were on Ser (88.1%) and Thr (11.0%),
whereas 0.8% phosphosites were at Tyr (Figure S2C). The high
inter-instrument correlation essentially provides a benchmark
for our quantification data, suggesting the phosphoproteomic
regulations, although they were mostly of <1.5 FCs, are not due
to experimental noise. To summarize, our integrative method
captured the phosphoproteomic snapshots at two time points
between three conditions (Ab vs. Con, GF vs. Con, and GF vs.
Ab), revealing phosphoproteome regulations are globally of a
small extent but biologically specific.
Significant Protein Phosphorylation
Regulated by Aβ25−35 and GFKP-19 and
Their Patterns
Given the relatively slow andmild effects on nerve cells of neuron
protective drugs, we set a filter criteria to better understand the
proteins whose phosphorylation were regulated by Aβ25−35 and
GFKP-19. This is because we hypothesize the more significantly
regulated phosphoproteome events are more closely related to
Aβ cytotoxicity and the protective mechanisms of GFKP-19.
The substantially changed phosphosites were screened as follows:
first, for both Con vs. Ab and GF vs. Ab, at least one of twice
the FC up than 1.5 was quantified by QE or HF; second, both
Con vs. Ab and GF vs. Ab undergo FC at least 1.5 or one of
them experience more than 1.2 FCs and another at least 1.5 FCs
(Figure 3A, Table S2). These highlighted phosphosites could be
critical to GFKP-19 function in response to the cell toxicity of
Aβ25−35, and analysis with heat map show very small change
in GF vs. Con and opposite change between Ab vs. Con and
GF vs. Ab (Figure S3). To interrogate which cell function the
filtered phosphosites participate in, GO annotation enrichment
for cellular function of the phosphoproteins was done. Notably,
cellular function like cytoskeleton protein binding, tubulin
binding, microtubule binding, cell projection, cell junction have
been enriched (Benjamini-Hochberg FDR threshold of 0.02 for
all processes, Figure 3B). Tau plays a vital role in the microtubule
assembly and stability. Main post-translational modification of
tau is phosphorylation which results in tau aggregation in
pathological situations (Avila et al., 2004). Neuron morphology
is formed by cytoskeletal scaffolding. Hyperphosphorylation of
tau is a premise for its aberrant aggregation and the formation
of NFTs, which is a main neuropathological characteristic of AD.
All of this suggests that Aβ25−35 and GFKP-19 treatment related
to the cell function that involved in AD progression.
To acquire a broad understand of the phosphorylation sites
and their sequence pattern significantly changed in experiment
group Ab vs. Con, GF vs. Con and GF vs. Ab, we carried out
motif enrichment with motif-x (Schwartz and Gygi, 2005) with
a P-value of ≤ 1.0E-6. The analysis was done separately to
the phosphopeptides that were up regulated or down regulated
in Ab vs. Con, GF vs. Con and GF vs. Ab (Figure S4).
More motifs were enriched for down regulated phosphosites
of GF vs. Ab. Taking focus on the results of GF vs. Ab
(Figure 4A), in the phosphosites up regulated we found an
enrichment of proline-directed (phosphor-Ser-X-X-X-phospho-
Ser-Pro), basophilic (Arg-phospho-Ser-X-phospho-Ser and Arg-
X-X-phospho-Ser-X-X-X-phospho-Ser), and basophilic at left
and basophilic at right (Arg-X-X-phospho-Ser-X-Asp) motifs,
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FIGURE 3 | Quantitative proteomics reveals protein phosphorylation regulated by Aβ25−35 and GFKP-19. (A) Screening changed phosphosites with the
standard: both Con vs. Ab and GF vs. Ab undergo FC at least 1.5 or one of them experience more than 1.2 FC and another at least 1.5 FC. Phosphosites identified
using QE and HF with FC meeting demand were drew as blue circles and the remaining phosphosites were drew as black circles. Black dash lines represent 1.5 FC
and gray dash lines represent 1.2 FC. (B) GO annotation enrichment of the phosphoproteins corresponding to the changed phosphosites.
whereas the phosphosites down regulated were enriched for
basophilic and proline-directed (phosphor-Ser-Pro-X-X-X-Arg)
motif (Figure 4B). The phosphorylation of proteins with these
motifs can possibly be regulated by Aβ25−35 and GFKP-19.
Further experiments are needed to verify the functional relevance
of AD for these phosphopeptide motif patterns.
GFKP-19 Potentially Regulates
Phosphorylation of Tau
How does GFKP-19 protect neuro-2a cells from the cytotoxicity
of Aβ25−35? β-Amyloid developing SPs in AD brain can lead
to the generation of superoxide radicals which react with
nitric oxide (NO) producing peroxynitrite and induces cell
injury subsequently. Meanwhile, NO has been suggested to be
associated to the pathogenesis of AD (Law et al., 2001). NO
is a free radical and can bind to superoxide anions to form
peroxynitrite (Eliasson et al., 1999), causing significant oxidative
stress. NO is produced by nitric oxide synthase (NOS) which has
three isoforms NOS1, NOS2, and NOS3. Overexpression of all
three isoforms of NOS is significantly involved in AD and the
initiation of the early progression of disease (de la Monte and
Wands, 2006). Phosphorylation of NOS1 at S852 activates NOS1
then increases NO production and protein phosphatase PP2B can
dephosphorylate NOS1 at S852 (Foster et al., 2009). We found
the phosphorylation of NOS1 at S847, which is corresponding
to S852 at human NOS1, is decreased by Aβ25−35 treatment and
rescued with GFKP-19 (Table S2). This suggests that GFKP-19
may bring down the oxidative damage and inflammation induced
by NO through suppressing its synthase NOS1.
Apoptosis-stimulating protein of p53 (ASPP2; encoded by
the Tp53bp2 gene) has been identified as an activator of
the p53 family. ASPP2 stimulates tumor suppressor protein
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FIGURE 4 | Motif analysis. (A) Motif analysis of phosphopeptides significantly changed in GF vs. Ab. Binary logarithm of the motif fold increase was used. Greater
fold change is displayed with deeper color. (B) Six enriched phosphosites motifs picked up from (A).
p53-mediated apoptotic response (Samuels-Lev et al., 2001;
Bergamaschi et al., 2004). ASPP2 can be phosphorylated at
S827 by the RAS/MAPK pathway which increases its binding
to p53 and enhances the transcription function of p53 (Godin-
Heymann et al., 2013). In our study, the phosphorylation of
ASPP2 at S479 was detected to increase when treated with
Aβ25−35 and was reversed with GFKP-19 treatment (Table S2).
The site of S479 has been identified in previous report (Mertins
et al., 2014), but the extract relationship between the ASPP2
protein function and this phosphosite is still unknown.
As we know, NFTs induced by hyperphosphorylation of tau
protein is one of the main neuropathological characteristics of
AD and has been a direction of AD treatment. Pre-clinical
studies on small molecule inhibitors of primary kinases involved
in tau phosphorylation to prevent hyperphosphorylation of tau
have shown promise (Khlistunova et al., 2007; Pickhardt et al.,
2007). According to previous study, there are six isoforms of tau
in human central nervous system (CNS) ringing in size from
352 to 441 amino acids, which generated by alternative splicing
(Hanger et al., 2009). Many kinases have been proved to be tau
kinases in earlier investigations (Vázquez-Higuera et al., 2011;
Martin et al., 2013). To identify the targets of these tau kinases,
large-scale studies aimed at determining phosphosites were done,
and produced much information as reference. Proline-directed
protein kinases of tau target Ser and Thr preceding a Pro residue
(SP/TP motif). Mitogen-activated protein kinases (MAPK), such
as p38 is contained in proline-directed protein kinases (Martin
et al., 2013).
In our results, 20 tau phosphosites were quantified and six
of them showed up regulation after Aβ25−35 treated in line with
previous reports that Aβ fibrils can increase tau phosphorylation
(Busciglio et al., 1995), and down regulated with GFKP-19
treatment. The six phosphosites are S491, T523, S648, S688, S692,
and S696 (Figure 5A, Figure S5, and Table S3), consistent to the
phosphosites S199, T231, S356, S396, S400, and S404 in human
tau isoform which had been reported before (Evans et al., 2000;
Thornton et al., 2011; Luo et al., 2014). The phosphorylation of at
S199 residue of tau is enriched in section of neurons vulnerable
to neurodegeneration and is an early marker of tau pathology
(Maurage et al., 2003). Phosphorylation at T231 has been
assumed an initiating event for the formation of NFTs and NFTs
induce neuronal cell death (Lasagna-Reeves et al., 2012). The
serine 356 site located in KXGSmotif promote tau disconnection
from microtubules which was probably a key site refer to AD
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FIGURE 5 | GFKP-19 decreases the phosphorylation of tau. (A) Fold change of tau phosphosites. The phosphorylation sites were S491, T523, S648, S688,
S692, and S696 in mouse tau. The three experiment groups Control, Aβ25−35 and Aβ25−35+GFKP-19 were represented with Con, Ab and GF. (B) Network analysis
of kinases, phosphatases and tau (MAPT). The physical interaction was provided by SIGNOR. Red represents up regulation in ratio (Aβ25−35+GFKP-19)/Aβ25−35
(GF vs. Ab), and green represents down regulation in GF vs. Ab. Interaction between MAPK14 and tau is shown with a red arrow.
(Abraha et al., 2000; Haase et al., 2004). The phosphorylation of
tau at sites Ser (396–404) was reported to represent an early event
in AD (Mondragón-Rodríguez et al., 2014). These suggest that
GFKP-19 can reverse Aβ25−35 treatment induced up regulation
of tau phosphorylation.
To identify if GFKP-19 regulates the phosphorylation of
tau through its kinase or phosphatases, interaction network
was produced with physical interaction prediction through
SIGNOR (Figure 5B). Protein phosphatase PP1 and PP2B are
phosphatases of tau dephosphorylating tau at S199, S202,
T205, T212, S214, S235, S262, S396, S404, and S409 and total
phosphatase activity and the activity of PP2B toward tau were
increased in AD brain (Liu et al., 2005). Expression product
of Ppp3ca is the catalytic subunit alpha isoform of PP2B.
We found the phosphorylation of Ppp3ca at S462 was up
regulated after treated with Aβ25−35 and was down regulated
by GFKP-19. The phosphorylation level of PP1 detected in
our study was unchanged. Tyrosine-protein kinase FYN has
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been reported to phosphorylate tau at T18, but the site was
not detected in our study, and the phosphorylation of FYN
at Y185 was slightly up regulated with GFKP-19 treatment
(Table S1), however, microtubule binding behavior of tau was
not significantly altered by tyrosine phosphorylation of tau
induced by FYN (Lee et al., 2004). Microtubule-associated
protein/microtubule affinity-regulating kinases (MARKs) have
been proved to phosphorylate the KXGS motifs of tau’s repeat
domain which is crucial for microtubules interactions and
aggregation (Drewes et al., 1997; Biernat et al., 2002). MARK2
can phosphorylates tau at S262 and the interaction between
MARK2 and tau was reported to be enhanced in AD brain section
(Gu et al., 2013). MARK2 was also demonstrated to selectively
phosphorylate eight serine residues in the repeat domain and C-
terminal tail of tau and impact the structure and microtubule
binding of tau (Schwalbe et al., 2013) and significant increase tau
phosphorylation level at S396/404 and decrease total tau levels
(Cavallini et al., 2013). We found that the phosphorylation of
MARK2 at S499 and S533 were down regulated after treated with
Aβ25−35 and reversed by GFKP-19, while these two sites were not
previously discovered for MARK2. Mitogen-activated protein
kinases (MAPK) are involved in tau hyperphosphorylation, and
p38MAPK has been reported to phosphorylate tau at S202, S205,
S231, S356, and S404 (Hanger et al., 2009). MAPK1 (ERK2) can
reduce phosphorylation of tau at S396 (Cavallini et al., 2013).
Dual phosphorylation of MAPK1 at T183 and Y185 could be
necessary for the activation of MAPK1 (Robbins et al., 1993)
and we found slightly increase in the phosphorylation level
of MAPK1 at these two sites induced by GFKP-19 treatment
(Table S1). MAPK14 (p38α) had been reported to be a potential
kinase of tau, and was related to a later onset of AD (Vázquez-
Higuera et al., 2011). Phosphorylation of MAPK14 at T180
is necessary for its activation, while phosphorylation at both
T180 and Y182 was more active than phosphorylation at T180
only (Zhang et al., 2008). Although we did not quantify the
phosphorylation of MAPK14 at Y182, we indeed detected the
change of the phosphorylation of MAPK14 at T180, a very close
phosphosite (Figure S6 and Table S4). The phosphorylation level
of MAPK14 at T180 was up regulated after Aβ25−35 treated, and
down regulated with GFKP-19 treatment, suggesting that GFKP-
19 may decrease tau phosphorylation through down regulating
the phosphorylation level of MAPK14 at T180.
CONCLUSIONS
Firstly, it was authenticated in the current study that cytotoxicity
induced by Aβ25−35 in neuro-2a cells could be successfully
reversed by GFKP-19 treatment within 24 h. Thus, quantitative
and comprehensive phosphoproteome analysis was carried out to
explore the possible protective mechanism of GFKP-19 whereby
treating neuro-2a cells with three different conditions (DMSO, 1
µMAβ25−35, 1 µMAβ25−35 + 1 µMGFKP-19).
Secondly, we screened the significantly changed phosphosites
and corresponding phosphoproteins and found that 4 h is a good
time point to inspect phosphorylation regulation. Gene Ontology
(GO) processes, such as cytoskeleton protein binding, cell
junction, and cell projection, were closely related to Aβ25−35 and
GFKP-19 treatment. Next, particular motifs of phosphorylation
sites were discovered, with which proteins were more possibly
to be regulated by Aβ25−35 and GFKP-19, while experiments are
further required.
Thirdly, we paid special attention to the proteins involved in
the hypothesis of AD. Down-regulated phosphorylation of NO
synthase NOS1 at S847 after Aβ25−35 treatment and its reverse
with GFKP-19 treatment led to a possible hypothesis that GFKP-
19may protect neuro-2a cells from the cytotoxicity of Aβ25−35 via
suppressing NO synthase NOS1 which in turn decrease oxidative
damage and inflammation induced by NO. As a crucial protein
involved in AD, tau was afterwards investigated for its relevance
with GFKP-19. It seems the phosphorylation level of tau increase
with Aβ25−35 treatment and phosphorylation treatment can
switch it. Meanwhile, potential tau kinase MAPK14 showed
phosphorylation change at T180, which was up regulated after
treated with Aβ25−35, and down regulated with the presence of
GFKP-19. The preliminary assumption is that GFKP-19 protects
neuro-2a cells from the damage of Aβ25−35 through decreasing
tau phosphorylation whichmay be realized by down regulation of
the phosphorylation level of MAPK14 at T180. We are currently
working on generating alternative hypothesis using our data set.
In general, our three-channel SILAC strategy labeled three
statuses, i.e., the control, the modeled disease, and the
drug protected status, which is further combined with deep
phosphoproteomic analysis enabled by extensive peptide-
level fractionation and high-resolution mass spectrometry,
providing a general framework to efficiently reveal the protective
mechanisms of potential drugs. This strategy captures even subtle
regulation events with a decent technical reproducibility and
should be valuable for future similar studies.
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